Premium
Clinicopathological implications of immunohistochemically demonstrated mucin core protein expression in hepatocellular carcinoma
Author(s) -
Ichikawa Tsuyoshi,
Yamamoto Takatsugu,
Uenishi Takahiro,
Tanaka Hiromu,
Takemura Shigekazu,
Ogawa Masao,
Tanaka Shogo,
Suehiro Shigefumi,
Hirohashi Kazuhiro,
Kubo Shoji
Publication year - 2006
Publication title -
journal of hepato‐biliary‐pancreatic surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.63
H-Index - 60
eISSN - 1868-6982
pISSN - 0944-1166
DOI - 10.1007/s00534-005-1070-4
Subject(s) - muc1 , medicine , hepatocellular carcinoma , immunohistochemistry , metastasis , mucin , hccs , pathology , carcinoma , oncology , gastroenterology , cancer
Methods We examined the expression of mucin core protein 1 (MUC1) immunohistochemically in 186 surgical specimens of histopathologically nonmucinous hepatocellular carcinoma (HCC) and compared the clinicopathological features in patients with MUC1‐positive HCC (MUC1‐positive group) with those in patients with MUC1‐negative HCC (MUC1‐negative group). Results MUC1 immunoreactively was present in 85 of the 186 HCCs. Of the clinicopathological variables examined, the serum concentration of α‐fetoprotein, tumor differentiation, bile duct invasion, lymph node metastasis, and cytokeratin 19 expression exhibited significant associations with MUC1 expression. Although cumulative and tumor‐free survival rates were not different between the two groups, the percentage of patients with first recurrence of HCC in distant organs (distant metastasis) within 2 years after surgery was significantly higher in the MUC1‐positive group than in the MUC1‐negative group ( P = 0.0104). The risk ratio of MUC1 positivity for this type of distant metastasis was 3.156 (95% confidence interval, 1.064–9.358). Conclusions In patients with MUC1‐positive HCC, careful follow‐up is necessary, not only for intrahepatic recurrence but also for distant metastasis, after the resection of primary HCC.